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Abstract
Background: HIV-associated neurocognitive disorder (HAND) remains highly prevalent despite effective anti-retroviral therapy
(ART). A number of adjunctive pharmacotherapies for HAND have been studied with disappointing results, but preliminary data
suggest that lithium may provide clinical beneﬁt. In addition, the low cost of lithium would facilitate access in low- and middle-income
countries which carry the greatest burden of HIV.
Methods:Our objective was to evaluate the 24-week efﬁcacy and safety of lithium in patients with moderate to severe HAND. Our
primary efﬁcacy endpoint was the change in Global Deﬁcit Score (GDS) from baseline to 24 weeks, whereas our secondary endpoint
was the change in proton magnetic resonance spectroscopy (1H-MRS) brain metabolite concentrations. We conducted a 24-week
randomized placebo-controlled trial of lithium as adjunctive pharmacotherapy. We enrolled participants with moderate to severe
HAND, on ART for at least 6 months, with suppressed viral loads and attending public sector primary care clinics in Cape Town,
South Africa. We randomized 66 participants to lithium (n=32) or placebo (n=34). Lithium or placebo was dosed 12-hourly and
titrated to achieve the maintenance target plasma concentration of 0.6 to 1.0mmol/L. Sham lithium concentrations were generated
for participants receiving placebo.
Results:Totally 61 participants completed the study (lithium arm=30; placebo arm=31). Participants at enrolment had amean age
of 40 years and a median CD4+ T-cell count of 500cells/mL. The median change in GDS between baseline and week 24 for the
lithium and placebo arms were –0.57 (95% conﬁdence interval [CI] –0.77, –0.32) and –0.56 (–0.69, –0.34) respectively, with a mean
difference of –0.054 (95%CI –0.26, 0.15); P=0.716. The improvement remained similar when analyzed according to age, severity of
impairment, CD4+ count, time on ART, and ART regimen. Standard 1H-MRS metabolite concentrations were similar between the
treatment arms. The study drug was well tolerated in both study arms. Six serious adverse events occurred, but none were
considered related to the study drug.Editor: Duane R. Hospenthal.
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Conclusion:Adjunctive lithium pharmacotherapy in patients on ART with HANDwas well tolerated but had no additional beneﬁt on
Decloedt et al. Medicine (2016) 95:46 Medicineneurocognitive impairment.
Abbreviations: 1H-MRS = proton magnetic resonance spectroscopy, AIDS = acquired immune deﬁciency syndrome, ART =
anti-retroviral therapy, CES-D =Center for Epidemiologic Studies Depression, Cho = choline, CI = conﬁdence interval, Cr = creatine,
DSMB = Data and safety monitoring board, eGFR = estimated glomerular ﬁltration rate, FDR = false discovery rate, GDS = Global
Deﬁcit Score, Glx= glutamate with glutamine, GSK-3-b= glycogen synthase kinase-3-beta, HAND=HIV-associated neurocognitive
disorder, mI =Myo-inositol, NAA = N-acetyl-aspartate, NAA+NAAG = N-acetyl-asparate with N-acetyl-aspartyl-glutamate, PACTR
= Pan African Clinical Trials Registry, TETRAS = TRG Essential Tremor Rating Assessment Scale.
Keywords: antiretroviral therapy, HIV, HIV neurocognitive impairment, lithium, Placebo, randomized controlled clinical trial, South
Africa
1. Introduction Test Non-Dominant Hand), psychomotor speed (Trail MakingHIV-associated neurocognitive disorder (HAND) remains highly
prevalent despite effective antiretroviral therapy (ART).[1,2] The
incidence of severe HAND has decreased, but with longer life
expectancy and associated risk factors for cerebrovascular
disease, the overall prevalence of HAND is projected to rise.[3,4]
HAND is associated with high rates of morbidity and
mortality.[1,5,6] Effective neuroprotective adjunctive pharmaco-
therapy for HAND has not yet been identiﬁed.
A number of adjunctive pharmacotherapies for HAND have
been studied with disappointing results thus far.[7] Preliminary
data suggest that lithium may provide clinical beneﬁt as
adjunctive pharmacotherapy. In 2 pilot studies, adjunctive
lithium in HAND improved neurocognitive impairment in 1
study, whereas neuronal integrity on imaging improved in both
studies.[8,9] However, these pilot studies were limited by both the
lack of a comparator arm and the short duration of lithium
treatment. Lithium has also been associated with an increase in
gray matter volume on neuroimaging in other patient popula-
tions.[10] In addition, lithium has been associated with an
improvement in neurocognitive impairment in patients with
Alzheimer’s disease.[11] Lithium has complex pharmacological
effects but unequivocal is the inhibition of glycogen synthase
kinase-3-beta (GSK-3-b), a serine-threonine protein kinase, that
mediates neuronal function, cellular substrates for learning and
memory, as well as neuronal apoptosis and inﬂammation
signaling pathways.[12–14] In addition to the potential promise
of lithium as an adjuvant from preliminary work, its low cost
would facilitate access in low- and middle-income countries
which carries the greatest burden of HIV.
We conducted a 24-week randomized placebo-controlled trial
to study lithium as an adjunctive pharmacotherapy in patients
with moderate to severe HAND.2. Methods
Our primary efﬁcacy endpoint was the change in the Global
Deﬁcit Score (GDS) from baseline to 24 week in the placebo arm
compared to the lithium arm. Baseline was the screening period
up to 4 weeks prior to enrolment (–4–0 weeks). During the
screening period all investigations and assessments were
performed and week 1 started when the participant was enrolled
and study drug dispensed. GDS summarizes the neuropsycho-
logical test results of selected cognitive domains and adjusts for
age, education, gender, and ethnicity.[15] The following domains
and tests were included: attention (Mental Alternation Test, Digit
Span, Paced Auditory Serial Addition Test), learning andmemory
(the Hopkins Verbal Learning Test), motor speed (Finger
TappingDominant Hand, Finger TappingNon-Dominant Hand,
Grooved Pegboard Test Dominant Hand, Grooved Pegboard2Test A, Color Trails Test 1, Digit Symbol-Coding), executive
function (Color Trails Test 2, Stroop Color-Word Test,
Wisconsin Card-Sorting Test), visual learning and memory
(Rey Complex Figure), and verbal ﬂuency (Animals and Fruit and
Vegetables). We screened for symptoms of depression using the
Center for Epidemiologic Studies Depression (CES-D) scale.[16]
Our secondary endpoint was the change between baseline (–4–0
weeks) and week 23 in proton magnetic resonance spectroscopy
(1H-MRS, TE30, and TR2000 ms) brain metabolite concen-
trations of glutamate, glutamate with glutamine (Glx), myo-
inositol (mI), N-acetyl-aspartate (NAA), N-acetyl-asparate with
N-acetyl-aspartyl-glutamate (NAA+NAAG), choline (Cho) and
creatine (Cr) in 3 brain areas (cortical: anterior cingulate cortex,
white matter: left frontal white matter and deep brain structure:
left thalamus). The primary safety endpoint was the severity and
frequency of adverse events.
2.1. Study design and participants
Inclusion criteria were HIV-infected adults (≥18 and 70 years),
established on ART for at least 6 months with a suppressed viral
load (HIV PCR <400copies/mL), cognitive impairment as
deﬁned by a GDS ≥ 0.5 attending public sector ART clinics in
Cape Town, South Africa. Enrolled participants were mainly
recruited from Nolungile Site C clinic in Khayelitsha and were
followed up at the University of Cape Town Clinical Research
Centre at Groote Schuur Hospital. Eligible participants gave
written informed consent; female participants were not pregnant
or breastfeeding and females of child-bearing potential commit-
ted to use of contraception. We required additional written
informed consent from each participant’s care giver as we
anticipated that participants may vary in their ability to provide
consent (participants may understand the need for ART and that
they have impaired memory, but may not be able to recall all
aspects of the study procedures and risks). Care givers had to
accompany participants to each study visit. We excluded
participants who received an investigational drug within 30
days, had evidence of an active acquired immune deﬁciency
syndrome (AIDS)-deﬁning opportunistic infection, had a history
of drug or alcohol abuse within 3 months before screening, had a
positive urine drug screen for drugs of abuse (amphetamine,
benzodiazepine, cannabis, cocaine, opiate), had conﬁrmed
neurosyphilis or vitamin B12 deﬁciency, had imaging structural
abnormalities, had a signiﬁcant head injury or severe mental
illness. We minimized the risk of lithium exposure by excluding
participants with a QTc greater than 450ms for males and 470
ms for females, conﬁrmed epilepsy on chronic treatment, use of
any medications that may predispose the participant to lithium
toxicity, clinically signiﬁcant hypo- or hyperthyroidism or
hypercalcaemia or hypermagnesaemia, renal impairment as
Table 1
Study procedures.
Week
–4 to 0 1 2 4 8 12 16 20 23 24
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 Visit 8 Visit 9 Visit 10 Visit 11 Visit 12
Informed consent x
Medical history and physical exam x
Lithium plasma concentration x x x x x x x x
Hematology
∗
x x
Chemistry† x x x x x x x
HIV viral load x x
b-HCG x x
Drug screen‡ x
Electrocardiography x x x x x x x
CD4+ T-cell count x x
Neuropsychological battery x x
Tremor measurement x x x x x x x x x
Magnetic resonance spectroscopy x x
Investigational drug dispensing x x x x x x
Adverse event monitoring x x x x x x x x x x
b-HCG=beta-human chorionic gonadotropin.
∗
Full blood count including differential.
† Screening: Treponema palllidum antibodies, vitamin B12, calcium, magnesium, thyroid stimulating hormone (T3 and T4 if TSH is abnormal), sodium, potassium, calcium, urea, and creatinine; Visit 6–12:
sodium, potassium, calcium, urea, and creatinine; repeat thyroid-stimulating hormone (T3 and T4 if TSH is abnormal) at visit 12.
‡ Drug screen included cocaine, amphetamine, opioids, cannabis, and benzodiazepines.
Assessed for eligibility (n=147)
Excluded  (n=81)
♦ Not meeting inclusion criteria (n=79)
♦ Declined to participate (n=2)
♦ Other reasons (n=0)
Analysed  (n=30)
• Excluded from analysis (n=0)
Lost to follow-up (n=1)
• Relocated (n=1)
Discontinued intervention (n=1)
• Inaccurate scholastic information 
provided at screening (n=1)
Allocated to lithium carbonate (n=32)
• Received allocated intervention (n=32)
Lost to follow-up (n=0)
Discontinued intervention (n=3)
• Developed major depressive disorder 
with alcohol use disorder (n=2)
• Traumatic brain injury not diagnosed 
at screening (n=1)
Allocated to placebo (n=34)
• Received allocated intervention (n=34)
Analysed  (n=31)
• Excluded from analysis (n=0)
Allocation
Analysis
Follow-Up
Randomised (n=66)
Enrollment
Figure 1. Diagram 1. Trial proﬁle: eligibility, randomization, follow-up, and analysis.
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Table 2
Baseline characteristics.
Baseline characteristic Lithium (n=32) Placebo (n=34) P
Gender
Male n=6 (18%) n=2 (6%) 0.149jj
Female n=28 (82%) n=30 (94%)
Age
∗
39.34±8.07 y 40.59±8.54 y 0.545‡
CD4+ T-cell count† cells/mm3 502 (394–648) 498 (384–651) 0.788x
Months on ART† 51 (23–74.5) 40 (25–71) 0.640x
ART regimen
NNRTI-based n=26 (81%) n=30 (88%) 0.327jj
PI-based n=6 (19%) n=4 (12%)
Neurocognitive impairment
GDS overall† 1.08 (0.83–1.44) 1.11 (0.82–1.53) 0.793x
GDS ≥ 1 n=20 (62.5%) n=20 (58.8%) 0.479jj
Decloedt et al. Medicine (2016) 95:46 Medicinedeﬁned as an estimated glomerular ﬁltration rate (eGFR) < 60
mL/min using the Cockroft and Gault formula and current
diarrhea with dehydration.
2.2. Intervention
We dosed lithium carbonate 250mg tablets (Camcolit, Norgine)
and matching placebo (donated by Norgine). The investigational
drugs were donated by Norgine who had no input into the study
design, conduct, or analysis. Lithium was titrated to achieve the
maintenance target plasma concentration of lithium in patients
with bipolar mood disorder of between 0.6 and 1.0mmol/L.
Sham lithium concentrations were generated for participants
receiving placebo (details in Section 2.4.)GDS < 1 n=12 (37.5%) n=14 (41.2%)
Neuromedical assessment
No disease n=18 (56%) n=24 (71%) 0.170jj
Mild-moderate disease n=14 (44%) n=10 (29%)
Severe disease n=0 n=0
Years education
≥ 10 n=18 (56%) n=18 (53%) 0.491jj
< 10 n=14 (44%) n=16 (47%)
Employment status
Employed¶ n=8 (25%) n=13 (38%) 0.187jj
Unemployed n=24 (75%) n=21 (62%)
Depression score
CES-D 9 (4–17) 8 (3–14) 0.672x
ART = anti-retroviral therapy, CES-D=Center for Epidemiologic Studies Depression scale, GDS=
Global Deﬁcit Score.
∗
Mean and standard deviation.
†Median and interquartile range.
‡ t-test (2 samples).
xWilcoxon sum rank.
jj Fisher’s exact test.
¶ Full-time or part-time work;2.3. Ethics and study oversight
The study was approved by the human research ethics
committees of the University of Cape Town (071/2013) and
Stellenbosch University (M13/07/027). The study was registered
on the Pan African Clinical Trials Registry (PACTR) with the
identiﬁer number PACTR201310000635418. An independent
data and safety monitoring board (DSMB) oversaw trial safety,
whereas the trial steering committee mainly monitored progress
of the trial.
2.4. Randomization, treatment concealment, and blinding
Participants in each cohort were randomized to placebo or the
lithium carbonate prior to the start of the study using block
randomization of 4, 6, or 8 which were subject to the overall
constraint of adding to the total sample size. Once an enrolment
number was assigned by the investigators, the study pharmacist
dispensed treatment according to the randomization list. The
statistician compiled the randomization list prior to study start.
The randomization list was stored in a secure place with access
limited to the statistician and pharmacist ensuring that the
investigators and participants remained blinded throughout the
study. Plasma concentrations were measured in both the lithium
and placebo arms by the laboratory. The laboratory remained
blinded and reported placebo concentrations as lower than level
of detection. The laboratory forwarded the concentration results
only to the study statistician. The study statistician generated
sham lithium concentrations for the placebo patients and
forwarded blinded concentrations (measured for lithium arm
and simulated for placebo arm) to a coinvestigator who had no
direct participant contact. This coinvestigator also received the
adverse event logs, and in conjunction with the blinded
concentrations, made dose-adjustment recommendations which
were forwarded to the treating investigators. Only the study
statistician was unblinded to arm allocation throughout this
process. The sham lithium values were generated based on a
random sampling from a distribution that was parameterized
with the true measured lithium concentrations in the treatment
arm, and with some additional rejection sampling to ensure the
sham lithium values did not fall outside of feasible ranges.
2.5. Adverse events and safety investigations
We reviewed participants weekly for adverse events for the ﬁrst
month followed by 4 weekly visits for adverse events and
adherence. Adherence was measured using pill counts and self-
report diary cards. Suspected poor adherence was ﬂagged by the
study pharmacist when a >25% discrepancy in doses taken and4the pill count was noted. Participants who were noted as
potentially being poorly adherent were intensively counseled by
the investigators and greater emphasis was placed on evaluating
adherence at subsequent visits. Participants with clinically
signiﬁcant adverse events were reviewed more frequently as
needed. At screening (–4 to 0 weeks) and week 24 we measured
full blood count and differential, Treponema palllidum anti-
bodies (screening only), vitamin B12 levels (screening only),
chemistry (calcium, magnesium, thyroid function, sodium,
potassium, calcium, urea, and creatinine), viral load, CD4+
count, urine screen for amphetamines, benzodiazepine, cannabis,
cocaine, and opiate abuse (screening only) and b-HCG. At other
visits (week 4, 8, 12, 16, 20), we measured lithium concentrations
(actual and sham) and chemistry (sodium, potassium, calcium,
urea and creatinine). Other safety investigations included
electrocardiogram (screening, week 4, 8, 12, 16, 20, 24) and
TRG Essential Tremor Rating Assessment Scale (TETRAS)
(screening, week 1, 2, 4, 8, 12, 16, 20, 24). Neuroimaging was
performed at baseline and week 23 (Table 1).2.6. Statistical methods
We calculated our sample size to detect an absolute value change
in GDS of 0.25 and required 49 participants per arm for 90%
power at alpha 0.05. We aimed to enroll 54 participants in each
arm to account for a 10% loss to follow-up or withdrawal.
Previous research has shown that ART alone improved the GDS
Table 3
Intent to treat analysis of neuropsychological changes.
Neuropsychological domain Baseline Lithium Baseline Placebo P Week 24 Lithium Week 24 Placebo P
Attention
Digit Span 6.06±1.27
∗
6.24±1.23
∗
0.577‡ 6.34±1.50
∗
6.62±1.35
∗
0.491‡
Paced Auditory Serial Addition Test 15.0 (12.0–19.5)† 16.00 (13.0–22.0)† 0.908x 17.50 (11.5–23.0)† 17.0 (14.0–24.0)† 0.792x
Learning and memory
Hopkins Verbal Learning Test (recall) 5.0 (5.0–6.0)† 6.0 (4.0–7.0)† 0.319x 7.0 (7.0–8.0)† 8.0 (5.0–9.0)† 0.773x
Motor speed
Finger Tapping nondominant hand 7.58 (6.70–8.73)† 7.83 (6.84–8.64)† 0.868x 6.78 (6.30–7.88)† 7.31 (6.28–8.16)† 0.256x
Grooved Pegboard Test non dominant hand 96.60 (79.96–123.04)† 101.43 (84.13–118.29)† 0.635x 80.36 (75.16–96.79)† 89.03 (80.94–103.58)† 0.0704x
Psychomotor speed
Trail Making Test A 59.54 (46.46–88.58)† 66.62 (51.54–83.7)† 0.386x 47.05 (36.71–55.63)† 50.92 (37.7–65.67)† 0.218x
Color Trails Test 1 58.84 (50.58–82.15)† 78.07 (58.71–95.44)† 0.041x 64.23 (47.39–76.13)† 69.82 (61.05–84.86)† 0.093x
Digit Symbol-Coding 28.84±10.55
∗
27.79±9.22
∗
0.668‡ 29.24±11.28
∗
28.97±10.36
∗
0.921‡
Executive function
Color Trails Test 2 154.82±45.95
∗
173.98±41.04
∗
0.078‡ 143.33 (111.52–169.12)† 146.44 (122.49–163.12)† 0.793x
Stroop Color-Word test 24.19±8.25
∗
23.88±8.53
∗
0.883‡ 26.84±9.17
∗
26.59±8.55
∗
0.907‡
Wisconsin Card-Sorting Test 41.0 (31.0–87.5)† 42.0 (33.0–57.0)† 0.797x 41.0 (29.5–59.5)† 38.0 (32.0–45.0)† 0.542x
Visual learning and memory
Rey Complex Figure (copy) 21.70±7.87
∗
21.91±8.0
∗
0.915‡ 21.70±7.87
∗
21.91±8.00
∗
0.915‡
Rey Complex Figure (3 min) 10.44±4.59
∗
10.56±3.89
∗
0.908‡ 10.44±4.59
∗
10.56±3.89
∗
0.908‡
Verbal ﬂuency
Animals 13.72±2.96
∗
13.71±3.75
∗
0.988‡ 14.06±2.66
∗
14.29±2.93
∗
0.738‡
Fruit and vegetables 14.06±3.05
∗
12.88±2.88
∗
0.111‡ 13.81±3.18
∗
13.38±3.24
∗
0.588‡
Depression score
CES-D 9 (4–17)† 8 (3–14)† 0.672x 3 (0–8)† 4 (0–7)† 0.643x
Summary score
Global Deﬁcit Score 1.08 (0.83–1.44)† 1.11 (0.82–1.53)† 0.793x 0.73 (0.35–0.92) 0.74 (0.44–1.12) 0.329x
CES-D=Center for Epidemiologic Studies Depression scale.
∗
Mean and standard deviation.
†Median and interquartile range.
‡ t-test (2 samples).
xWilcoxon sum rank.
Decloedt et al. Medicine (2016) 95:46 www.md-journal.comby a mean of 0.13 and 0.6 in patients with a GDS in the mild
to moderate (>0.25 to <0.75) and severe (>0.75) ranges,
respectively.[8,17] Twelve week adjunctive lithium therapy in
patients stable on ART improved the GDS by 0.3 and we opted to
detect a more conservative GDS difference of 0.25 with a
standard deviation of 0.375, which was calculated using the
range in the published studies divided by 4.[8,17] We conducted an
intention-to-treat and per protocol analysis for the primary
endpoint. For the intention-to-treat analysis, we carried over the
last data points when the week 24 endpoints were missing,
example for missing GDS at week 24 we used GDS at enrolment.
For the per protocol analysis, we included only participants who
completed the treatment originally allocated. We assessed the
normality of the data visually and using the Shapiro–Wilk test.
We compared baseline and week 24 values of continuous
variables with paired t-tests or Wilcoxon sum rank depending on
the distribution. Normally distributed data were described using
the mean and standard deviation, whereas non-normally
distributed data were described using median and interquartile
ranges. We applied correction for the false discovery rate (FDR)
by the method of Benjamin & Hochberg to comparisons. We
report raw P values throughout and note any P values that lose or
gain statistical signiﬁcance after correction.3. Results
We enrolled our ﬁrst participant in December 2013 and had our
last study visit in June 2015. Due to slow accrual we were unable
to enroll our original calculated sample size and randomized 665participants to lithium (n=34) or placebo (n=32), whereas 61
participants completed the study (lithium arm=30; placebo
arm=31) (diagram 1). All participants were black Africans, ﬁrst
language Xhosa. Baseline characteristics were similar between
the 2 groups with the majority of participants presenting with
severe neurocognitive impairment with GDS of ≥ 1 (Table 2).
Suspected poor adherence was similar in the placebo and
lithium arms. We recorded 47 poor adherence episodes of which
23 episodes occurred in 16 lithium arm participants and 24
episodes occurred in 17 placebo arm participants. In the 16
lithium arm participants: 10 participants had 1 poor adherence
episode, 5 participants had 2 poor adherence episodes, and 1
participant had 3 poor adherence episodes. In the 17 placebo arm
participants: 12 participants had 1 poor adherence episode, 3
participants had 2 poor adherence episodes, and 2 participants
had 3 poor adherence episodes. The majority of poor adherence
episodes occurred within the ﬁrst 8 weeks of the study (57%).
Week 24 viral loads were not predictive of poor adherence as the
2 participants with slightly raised viral loads at the end of the
study (highest value 585 copies per mL) were not identiﬁed with
poor adherence. Both participants were allocated to the lithium
arms.
The improvement in GDS was not different between the
treatment arms in both the intent-to-treat and the per protocol
analysis (Table 3, supplemental ﬁle table 1, http://links.lww.com/
MD/B409, diagram 2 (A) (B)). The median change in GDS scores
between baseline and week 24 for the lithium and placebo arms
were –0.57 (95% CI –0.77, –0.32) and –0.56 (–0.69, –0.34)
respectively, with a mean difference of –0.054 (–0.26, 0.15);
Figure 2. Diagram 2. Box-and-whisker plots of (GDS) at week 1 and week 24
analyzed (A) per protocol analysis and (B) intention to treat analysis. GDS =
Global Deﬁcit Score.
Table 4
Selected adverse events considered relevant to lithium therapy.
Adverse events Severity
Lithium
(n=32)
Placebo
(n=34)
Cardiac disorders
First degree heart block Mild 1 (2.9%) 1 (3.1%)
Bradycardia Mild 2 (5.9%) 1 (3.1%)
Tachycardia Mild 0 1 (3.1%)
QTc prolongation Mild 11 (32.4%) 14 (43.8%)
Moderate 1 (2.9%) 0
ST-elevation Mild 0 1 (3.1%)
T-wave changes Mild 2 (5.9%) 0
Endocrine disorders
Hypothyroidism Mild 2 (5.9%) 0
Weight gain Mild 1 (2.9%) 0
Symptoms of nephrogenic diabetes Mild 1 (2.9%) 0
Moderate 2 (5.9%) 0
Gastrointestinal disorders
Abdominal cramps Mild 2 (5.9%) 0
Constipation Mild 0 1 (3.1%)
Diarrhoea Mild 6 (17.6%) 7 (21.9%)
Moderate 2 (5.9%) 1 (3.1%)
Dyspepsia Mild 0 1 (3.1%)
Gastroenteritis Mild 0 1 (3.1%)
Increased stool frequency Mild 0 1 (3.1%)
Loose stool Mild 0 2 (6.3%)
Investigations
Hyperkalaemia Mild 1 (2.9%) 1 (3.1%)
Moderate 1 (2.9%) 0
Hypermagnesemia Mild 1 (2.9%) 0
Hypomagnesemia Mild 1 (2.9%) 0
Hypocalcaemia Mild 2 (5.9%) 3 (9.4%)
Low vitamin B12 Mild 1 (2.9%) 0
Raise in viral load Mild 2 (5.9%) 0
Nervous system disorders
Dizziness Mild 6 (17.6%) 4 (12.5%)
Headache Mild 4 (11.8%) 12 (37.5%)
Moderate 0 1 (3.1%)
Upper limb tremor Mild 26 (76.5%) 26 (81.3%)
Lower limb tremor Moderate 1 (2.9%) 0
Psychiatric disorders
Daytime somnolence Mild 2 (5.9%) 0
Insomnia Mild 1 (2.9%) 0
Major depressive disorder
with comorbid alcohol use
Severe 0 2 (6.3%)
Renal disorders
Decrease in estimated
glomerular ﬁltration rate
Mild 1 (2.9%) 2 (6.3%)
Total 81 (49.4%) 83 (50.6%)
Decloedt et al. Medicine (2016) 95:46 MedicineP=0.716. The improvement remained similar when analysed
according to age, severity of impairment, CD4+ count, time on
ART, and ART regimen. 1H-MRS metabolite concentrations
(supplemental ﬁle table 2, http://links.lww.com/MD/B409) were
also not different between the treatment arms. However, the 1H-
MRS metabolite concentrations could not be measured for all
participants due to intermittent periods of technical downtime of
the MRI scanner. The study drug was well tolerated with no
statistically signiﬁcant difference (P=0.413) in total adverse
events between the 2 study arms (Table 4). Six serious adverse
events occurred but none were considered related to the study
drug (supplemental ﬁle table 3, http://links.lww.com/MD/B409).
4. Discussion
Our study is the ﬁrst to test adjunctive lithium therapy in patients
with HAND in a randomized double blind controlled trial for a
period of 6 months. We found that adjunctive lithium in patients
with HAND was well tolerated but had no beneﬁt on neuro-
cognitive impairment compared with placebo when assessing
neuropsychological test performance and 1H-MRS metabolite
concentrations. Neurocognitive impairment improved similarly
in both the lithium and placebo arm.
Lithium has demonstrated neuroprotection with an increase in
gray matter volume in various patient populations.[10,13]
However, controlled clinical data demonstrating neuroprotec-6tion with clinical endpoints were lacking. The improvement in
GDS we observed in the lithium arm is similar to the
improvement noted by Letendre et al[8] (median improvement
0.29 while we found a median improvement of 0.47) in an open-
label 12-week lithium study in patients with HAND. The similar
improvement we observed in the placebo arm highlights the
importance of a comparator arm. There are a number of potential
explanations for our ﬁndings that lithium was no better than
placebo. First, the placebo effect is a well-described response
accompanied by psychobiological changes in the brain.[18]
Clinicians are held in high regard and could have biased our
participants’ expectations and response.[19] Second, participants
may have become more familiar with the neuropsychological
assessments leading to a practice effect. We deliberately
scheduled the neuropsychological assessments 6 months apart
Decloedt et al. Medicine (2016) 95:46 www.md-journal.comto limit a potential practice effect, but cannot completely exclude
some practice effect. In addition, no participant underwent a
neuropsychological assessment prior to enrolment into this study.
Third, we assessed endpoints only twice 6 months apart which
prevents a longitudinal description of natural disease progres-
sion, placebo response, and lithium effect. The trajectory of
natural disease, placebo, and lithium would be best described in
longer term studies where quantitative modeling is applied.[20]
The possibility exists that the placebo response may be
temporary. Fourth, cognitive assessment is inﬂuenced by HIV
infection, physical -, psychiatric -, and social comorbidity.[21] We
monitored HIV -, physical- and psychiatric comorbidities and did
not detect an improvement, but it is plausible that we missed
social comorbidity improvement explained by trial participation.
Lastly, it is possible that only patients with certain covariates or
characteristics (such as depression comorbidity) may respond
signiﬁcantly better to lithium compared with placebo. Recently a
genome-wide association between lithium response and common
genetic variants on chromosome 21 has been identiﬁed in patients
with bipolar disorder.[22]
Our study has a number of differences when compared with
the open-label pilot studies of adjunctive lithium in HAND:
longer study duration, randomized double-blind placebo-con-
trolled design, lithium, and placebo dose adjusted using
therapeutic drug monitoring with a target range used in the
treatment of bipolar mood disorder and mostly African female
participants.[8,9] The Letendre et al[8] study found that lithium
improved the GDS from impaired to normal after 12 weeks in 8
participants, whereas Schifﬁtto et al found no neurocognitive
improvement after 10 weeks in 13 participants, but found a
decrease in glutamate with glutamine (Glx) metabolites in the
frontal gray matter.[8,9] However, both studies were uncon-
trolled.
Our study has a number of limitations. First, our ﬁndings are
limited by the fact that we were unable to enroll our original
calculated sample due to slow accrual. However, an increase in
sample size is unlikely to change our ﬁndings as an interim review
by the DSMB determined that a sample size of 65 using the same
assumptions as the original calculation have a power of 70% to
90% for the standard deviation ranging from 0.3 to 0.5. Our
GDS standard deviation was 0.53 and 0.39 in the placebo and
lithium arms, respectively. To the contrary, the between-group
difference of GDS may be smaller than the assumed 0.25 and an
even larger sample size than originally calculated may have been
required to detect a signiﬁcant difference. Second, 6 month trial
duration could not exclude a beneﬁcial effect of lithium on long-
term functional worsening. Third, we cannot exclude selection
bias as the majority of our participants were unemployed females
with signiﬁcant neurocognitive impairment. Fourth, all our
participants were black Xhosa speaking Africans which limits the
generalizability of our results.
In summary, we found no additional beneﬁt of adjunctive
lithium to placebo in African patients with HAND after 6 months
of treatment. Future adjunctive lithium studies should follow-up
patients for a longer duration to determine whether lithium has a
beneﬁcial effect on HAND progression.Acknowledgments
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